Researchers from the Massachusetts General Hospital Cancer Center and Boston University School of Medicine have identified the first potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate. Treatment with a small molecule that blocks a key step in the alternative lengthening of telomeres pathway was able to inhibit the growth and survival of ALT-positive tumor cells.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.